[go: up one dir, main page]

MA52977A - Composés de cyanotriazole et leurs utilisations - Google Patents

Composés de cyanotriazole et leurs utilisations

Info

Publication number
MA52977A
MA52977A MA052977A MA52977A MA52977A MA 52977 A MA52977 A MA 52977A MA 052977 A MA052977 A MA 052977A MA 52977 A MA52977 A MA 52977A MA 52977 A MA52977 A MA 52977A
Authority
MA
Morocco
Prior art keywords
cyanotriazole
compounds
cyanotriazole compounds
Prior art date
Application number
MA052977A
Other languages
English (en)
Inventor
Jan Jiricek
Shuyi Pearly Ng
Srinivasa P S Rao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA52977A publication Critical patent/MA52977A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052977A 2018-06-19 2019-06-18 Composés de cyanotriazole et leurs utilisations MA52977A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862687045P 2018-06-19 2018-06-19

Publications (1)

Publication Number Publication Date
MA52977A true MA52977A (fr) 2021-04-28

Family

ID=67841115

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052977A MA52977A (fr) 2018-06-19 2019-06-18 Composés de cyanotriazole et leurs utilisations

Country Status (21)

Country Link
US (1) US20220106296A1 (fr)
EP (1) EP3810598A1 (fr)
JP (1) JP2021528397A (fr)
KR (1) KR20210022646A (fr)
CN (1) CN112313217A (fr)
AU (1) AU2019291490B2 (fr)
BR (1) BR112020025538A2 (fr)
CA (1) CA3100954A1 (fr)
CL (1) CL2020003252A1 (fr)
CR (1) CR20200619A (fr)
CU (1) CU20200102A7 (fr)
EA (1) EA202190064A1 (fr)
EC (1) ECSP20080991A (fr)
IL (1) IL279483A (fr)
JO (1) JOP20200327A1 (fr)
MA (1) MA52977A (fr)
MX (1) MX2020013729A (fr)
PE (1) PE20210780A1 (fr)
PH (1) PH12020552186A1 (fr)
SG (1) SG11202012628XA (fr)
WO (1) WO2019244049A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115181060B (zh) * 2022-08-19 2024-03-19 江苏禾裕泰化学有限公司 一种生产2-氨基-3-氯-5-三氟甲基吡啶的清洁生产工艺
CN116284772B (zh) * 2023-02-09 2024-02-27 四川大学 一种联吡啶三唑共价有机聚合物及其制备方法和应用
CN116836111A (zh) * 2023-09-01 2023-10-03 峰成医药科技(天津)有限公司 一种氟代吡啶的连续化合成方法
WO2025163522A1 (fr) * 2024-01-31 2025-08-07 Novartis Ag Composés de cyanotriazole et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
EP2790705B1 (fr) * 2011-12-15 2017-12-06 Novartis AG Utilisation d'inhibiteurs de l'activité ou de la fonction de pi3k
BR112017013545A2 (pt) * 2014-12-22 2018-03-06 Glaxosmithkline Ip Dev Ltd composto de tiotriazol e seu uso em infecções por protozoários parasíticos

Also Published As

Publication number Publication date
KR20210022646A (ko) 2021-03-03
CN112313217A (zh) 2021-02-02
PH12020552186A1 (en) 2021-06-07
CL2020003252A1 (es) 2021-07-09
CA3100954A1 (fr) 2019-12-26
JP2021528397A (ja) 2021-10-21
CU20200102A7 (es) 2021-08-06
AU2019291490B2 (en) 2022-02-10
EA202190064A1 (ru) 2021-03-29
PE20210780A1 (es) 2021-04-21
AU2019291490A1 (en) 2021-02-04
ECSP20080991A (es) 2021-02-26
CR20200619A (es) 2021-01-21
IL279483A (en) 2021-01-31
EP3810598A1 (fr) 2021-04-28
US20220106296A1 (en) 2022-04-07
JOP20200327A1 (ar) 2020-12-15
MX2020013729A (es) 2021-05-12
BR112020025538A2 (pt) 2021-03-16
WO2019244049A1 (fr) 2019-12-26
SG11202012628XA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
EP3917529A4 (fr) Composés et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
EP3917527A4 (fr) Composés et leurs utilisations
MA52365A (fr) Composés et leurs utilisations
EP3694861A4 (fr) Composés hétérocycliques et leurs utilisations
MA52092A (fr) Composés et leurs utilisations
MA55385A (fr) Composés et leurs utilisations
EP3849983A4 (fr) Composés de triazolo-pyrimidine et leurs utilisations
MA52483A (fr) Dérivés de gip et leurs utilisations
EP3787607A4 (fr) Compositions de caroténoïdes et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3337486A4 (fr) Composés deutérés et leurs utilisations
EP3810182A4 (fr) Néoantigènes et leurs utilisations
MA43205A (fr) Composés pyy sélectifs et leurs utilisations
EP3790883A4 (fr) Composés hétéroaryles et leurs utilisations
MA50173A (fr) Composés activateurs de bisamide sarcomère et leurs utilisations
EP3838900A4 (fr) Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées
EP3846807A4 (fr) Composés d'imidazoquinoléine et leurs utilisations
MA45857A (fr) Composés et compositions, et utilisations associées
MA54829A (fr) Composés et leurs utilisations
EP3426255A4 (fr) Composés antibactériens et utilisations de ceux-ci
EP3853216A4 (fr) Composés substitués par pyridinyle et leurs utilisations
EP3450444A4 (fr) Composés de type crocine et utilisations correspondantes
MA48956A (fr) Composés mic-1 et utilisations associées
EP3856741A4 (fr) Composés polymorphes et leurs utilisations